Cerebrospinal fluid levels of inflammation, oxidative stress and NAD\(^+\) are linked to differences in plasma carotenoid concentrations

Jade Guest\(^1,2\), Ross Grant\(^1,2,3\)*, Manohar Garg\(^4\), Trevor A Mori\(^5\), Kevin D Croft\(^5\) and Ayse Bilgin\(^6\)

Abstract

**Background:** The consumption of foods rich in carotenoids that possess significant antioxidant and inflammatory modulating properties has been linked to reduced risk of neuropathology. The objective of this study was to evaluate the relationship between plasma carotenoid concentrations and plasma and cerebrospinal fluid (CSF) markers of inflammation, oxidative stress and nicotinamide adenine dinucleotide (NAD\(^+\)) in an essentially healthy human cohort.

**Methods:** Thirty-eight matched CSF and plasma samples were collected from consenting participants who required a spinal tap for the administration of anaesthetic. Plasma concentrations of carotenoids and both plasma and cerebrospinal fluid (CSF) levels of NAD(H) and markers of inflammation (IL-6, TNF-\(\alpha\)) and oxidative stress (F2-isoprostanes, 8-OHdG and total antioxidant capacity) were quantified.

**Results:** The average age of participants was 53 years (SD = 20, interquartile range = 38). Both \(\alpha\)-carotene (\(P = 0.01\)) and \(\beta\)-carotene (\(P < 0.001\)) correlated positively with plasma total antioxidant capacity. A positive correlation was observed between \(\alpha\)-carotene and CSF TNF-\(\alpha\) levels (\(P = 0.02\)). \(\beta\)-cryptoxanthin (\(P = 0.04\)) and lycopene (\(P = 0.02\)) inversely correlated with CSF and plasma IL-6 respectively. A positive correlation was also observed between lycopene and both plasma (\(P < 0.001\)) and CSF (\(P < 0.01\)) [NAD(H)]. Surprisingly no statistically significant associations were found between the most abundant carotenoids, lutein and zeaxanthin and either plasma or CSF markers of oxidative stress.

**Conclusion:** Together these findings suggest that consumption of carotenoids may modulate inflammation and enhance antioxidant defences within both the central nervous system (CNS) and systemic circulation. Increased levels of lycopene also appear to moderate decline in the essential pyridine nucleotide [NAD(H)] in both the plasma and the CSF.

**Keywords:** Brain, Carotenoid, Inflammation, NAD\(^+\), Oxidative stress

---

**Background**

Neuroinflammation and oxidative stress have emerged as key players in the complex interplay between environmental and biological factors involved in the development of neurodegenerative disease [1,2]. Under normal homeostatic conditions both immune and oxidative activity are largely transitory due to inherent negative feedback mechanisms including increased production of anti-inflammatory cytokines and enhanced endogenous antioxidant (that is glutathione peroxidase, catalase or superoxide dismutase) activity. During periods of chronic disease however, these processes can be continuously activated often amplifying each other in a positive feed forward cycle, causing cell death, tissue dysfunction and disease [3,4].

Neuroinflammation is a well-established feature of the pathology associated with most neurodegenerative disorders [5-7]. During various stages of disease the activity of microglia and astrocytes are markedly increased resulting in altered production of important signalling molecules such as cytokines [8,9]. Secretion of the inflammatory cytokines TNF and IL-6 are reportedly upregulated within the central nervous system (CNS) of a...
number of neurodegenerative disorders including Alzheimer’s disease (AD) [10]. While elevated levels of TNF and IL-6 have been found to induce neuronal apoptosis and tau protein phosphorylation respectively [11-14], observations that IL-6 and TNF inhibit glutamate and β-amyloid (Aβ) toxicity respectively also indicate potentially neuroprotective roles [15,16]. At lower concentrations TNF has also been shown to be involved in synaptic scaling, cell signalling and a number of behavioural and autonomic processes, leading some to consider this cytokine as a neuromodulator [17-22]. Likewise, physiological levels of IL-6 have been shown to possess neuromodulatory properties, enhancing the differentiation of neurons and expression and function of the neuronal adenosine A1 receptor, an important modulator of synaptic transmission [23,24]. Evidence is thus emerging that cytokines such as TNF and IL-6 can elicit either positive modulatory or toxic effects in the CNS that is likely dependent on their level of expression.

While the complex pathological and physiological roles of inflammatory cytokines in the CNS are yet to be fully understood, it is relatively well established that elevated levels of each of these cytokines directly promote oxidative stress [25-27]. The brain, and neurons in particular, are especially vulnerable to oxidative stress as a consequence of their poor antioxidant protection, high oxygen demand and high levels of both polyunsaturated fatty acids and transition metals [28]. The term ‘oxidative stress’, describes a significant imbalance between antioxidant defences and the bodies’ formation of reactive nitrogen (RNS) and/or oxygen species (ROS) [29]. Accumulation of RNS/ROS may result in a variety of detrimental effects such as protein oxidation, lipid peroxidation and DNA damage [2]. Failure to repair this damage, particularly to the DNA, has been demonstrated to cause genomic instability and neuronal apoptosis and is associated with the development of several neuropathologies [2,30-32].

In order to maintain cellular integrity and homeostasis after oxidative assault, a number of repair processes exist including activation of the nicotinamide adenine dinucleotide (NAD⁺) dependent DNA nick sensor poly(ADP-ribose) polymerase-1 (PARP) [33]. Importantly PARP activation in response to DNA damage catalyses the successive cleavage of the ADP-ribose moiety from NAD⁺ resulting in the formation of poly(ADP-ribose) subunits. In the context of low-to-moderate DNA damage this process facilitates DNA repair. However, over-activation of PARP, due to excessive DNA damage, can result in neuronal death as a consequence of decreased ATP production following critical depletion of NAD⁺ [34]. In order to preserve cellular energy and concomitantly PARP activity, adequate levels of NAD⁺ must be maintained.

While age is the major risk factor for the development of most neurodegenerative disorders [35,36], a number of lifestyle choices have been linked to either promotion or prevention of pathogenesis by increasing or decreasing oxidative stress and inflammation. Carotenoids, a family of phytochemicals synthesised by plants, that are responsible for the red, orange, and yellow pigments of fruit and vegetables, have been the subject of increased attention as a result of their antioxidant and inflammatory modulating properties. Importantly, serum carotenoids have been shown to be positively associated with brain carotenoid levels and can be considered a reliable predictor of brain carotenoid concentrations [37].

Within the brain, carotenoids are thought to exert a variety of protective effects. In a cell culture model of AD, lycopene was shown to efficiently attenuate Aβ-induced ROS formation, improve neuron viability and decrease the rate of apoptosis [38]. Low serum levels of lycopene, β-carotene, lutein and zeaxanthin have also been linked to impaired cognitive function and AD [39-42]. Lutein supplementation has also been shown to prevent erythrocyte lipid peroxidation in humans and has been suggested as a potential therapy for the prevention of dementia [43].

Collectively, these reports indicate that higher carotenoid levels may mitigate against the development of an oxidative-inflammatory state and thereby reduce tissue damage within the CNS. While evidence from cell culture, animal and limited post-mortem brain tissue studies support this hypothesis, to date no study has investigated this putative association in the CNS of a healthy human cohort. Therefore the objective of this study was to evaluate the relationship between plasma concentrations of carotenoids and plasma and cerebrospinal fluid (CSF) markers of inflammation, oxidative stress and NAD⁺ in an essentially healthy human cohort.

Methods
Ethics statement
This study was conducted in accordance with the Helsinki declaration. Ethical approval was obtained from the Human Research Ethics Committee, Sydney Adventist Hospital (EC00141, project number 2011-005). Written informed consent was obtained from all participants prior to commencement.

Participants
Male (n = 10) and female (n = 28) participants, who required a spinal tap for the administration of anaesthetic as part of routine care (that is prior to surgery), were recruited at Sydney Adventist Hospital, Australia as part of a larger health study [44]. The average age of participants was 53 years (SD = 20, interquartile range = 38). Participants were excluded from the cohort if they were smokers or had a confirmed diagnosis of a neurological/neurodegenerative disorder or CNS infection. In total thirty-eight CSF
and matched blood samples were collected from consenting participants considered in general good health.

Sample collection
CSF and blood samples (fasting ≥ ten hours) were collected by an anaesthetist no longer than 30 minutes apart. Blood was collected into heparinised tubes from a superficial vein on an upper limb, prior to the administration of fluids or anaesthetics. CSF samples were collected via standard lumbar puncture prior to injection of anaesthetics. Samples were centrifuged for 10 minutes at 1,800 rpm and stored at −194°C within 1 hour of collection, for a maximum of 12 months, until analysis. Samples intended for F2-isoprostane analysis where stored in the presence of a glutathione/butylated hydroxytoluene preservative.

Biochemical analysis
Total nicotinamide adenine dinucleotide (NAD(H)) concentrations were measured spectrophotometrically using a thiazolyl blue microcycling assay established by Bernofsky and Swan [45], and adapted to a 96-well plate format by Grant and Kapoor as previously described [46,47].

IL-6, TNF-α, total antioxidant capacity (TAC) and 8-hydroxy-2′-deoxyguanosine (8-OHdG) were measured using a standardised commercial solid phase sandwich enzyme-linked immuno sorbent assay (ELISA) (Human IL6 High Sensitivity ELISA Kit, Abcam, Cambridge, MA, USA; Human TNF-α UltraSensitive, Invitrogen Corporation, Camarillo, CA, USA; Antioxidant Assay Kit, Cayman Chemical Company, Ann Arbor, MI, USA; Highly Sensitive 8-OHdG Check, Japan Institute for the Control of Ageing, Shizuoka Japan).

Total F2-isoprostanes were measured by gas chromatography-mass spectrometry (GC-MS) using electron capture negative ionisation according to a modification in the method of Mori et al. as previously described [48,49].

Plasma carotenoids were measured using high-performance liquid chromatography according to the method established by Barua and colleagues and previously described (Figure 1) [50,51].

Statistical analysis
Statistical analyses were performed using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA). Data is presented as means ± standard deviation (SD) unless otherwise stated. The Pearson correlation coefficient and multiple linear regression, controlling for age and gender, was used to identify significant relationships between carotenoids, [NAD(H)], and markers of oxidative stress and inflammation. Normality was assessed using histogram, Shapiro-Wilk and Kolmogorov-Smirnov analysis. Because some carotenoids (lutein and zeaxanthin, β-cryptoxanthin, lycopene, total carotenoids) and both plasma and CSF IL-6 showed slightly skewed distributions, analyses were performed using base-10 log-transformed data. Adjusted and non-adjusted P-values are provided throughout with test significance set at P-value ≤ 0.05.

Results
The mean plasma concentrations of individual carotenoid pigments are presented in Table 1.

Association between carotenoids and inflammatory cytokines
A significant inverse association was observed between plasma levels of lycopene and plasma IL-6 (P < 0.001, r = −0.53, n = 34) (Figure 2A). This association remained even after controlling for age and gender (P = 0.02, R² = 0.21). An increase in lycopene of 1% was associated, on average, with a 0.54% decrease in plasma IL-6. Higher plasma total carotenoid concentrations were also associated with lower levels of plasma IL-6 (P = 0.01, r = −0.44, n = 34) (Figure 2B), however this relationship did not remain statistically significant after controlling for age and gender (P = 0.06). No associations were found between plasma IL-6 and any other individual carotenoid.

An increase in plasma β-cryptoxanthin levels was associated with a decrease in CSF IL-6 (P = 0.04, r = −0.34, n = 36) (Figure 2C). This association remained even after controlling for age and gender (P = 0.04, R² = 0.45). An increase in β-cryptoxanthin by 1% was associated, on average, with a 0.33% decrease in CSF IL-6. Higher plasma total carotenoids were also associated with reduced levels of CSF IL-6 (P = 0.01, r = −0.44, n = 36) however this relationship did not remain statistically significant after controlling for age and gender (P = 0.06) (Figure 2D). A trend between increased plasma lycopene levels and reduced concentrations of CSF IL-6 was observed, however this was not statistically significant (P = 0.22). No associations were found between CSF IL-6 and any other individual carotenoid.

An increase in plasma α-carotene was associated with an increase in CSF TNF-α (P = 0.01, r = 0.185, n = 36) (Figure 3). This association remained even after controlling for age and gender (P = 0.02, R² = 0.10). A ten-fold increase in α-carotene was associated with a small 0.003 pg/mL increase in CSF TNF-α. A positive trend between β-carotene and CSF TNF-α was also observed, however this did not reach statistical significance (P = 0.17). No associations were found between CSF TNF-α and any other individual carotenoid.

Association between carotenoids and markers of oxidative stress
A significant positive association was observed between both α-carotene (P = 0.01, r = 0.43, n = 33) and β-carotene (P < 0.001, r = 0.59, n = 33) and the total antioxidant
capacity (TAC) in plasma (Figure 4). These relationships remained even after controlling for age and gender ($P = 0.01$, $R^2 = 0.14$; $P < 0.001$, $R^2 = 0.32$ respectively). A 1 ng/mL increase in α-carotene or β-carotene was associated with a 0.15 or 0.04 nmol/mg protein increase in plasma TAC respectively. When controlling for age and gender, higher plasma levels of lycopene also tended to correspond with reduced levels of plasma F2-isoprostanes, however this did not quite reach statistical significance ($P = 0.06$). An apparent inverse trend between CSF F2-isoprostane levels and plasma β-cryptoxanthin ($P = 0.16$), α-carotene ($P = 0.14$) and β-carotene ($P = 0.20$) was observed, though these did not reach statistical significance ($P = 0.06$). After controlling for age and gender a positive association between total carotenoids and plasma NAD(H) levels was also observed ($P = 0.03$, $R^2 = 0.12$, $n = 37$) (Figure 5C). A 1% increase in total carotenoids was associated, on average, with a 0.21% increase in plasma [NAD(H)]. No further associations were found between plasma [NAD(H)], CSF [NAD(H)] and any other individual carotenoid.

### Table 1 Mean plasma carotenoid concentrations

| Carotenoid                  | Mean (ng/mL) ± SD |
|-----------------------------|-------------------|
| Lutein and zeaxanthin       | 538.24 ± 338.15   |
| β-cryptoxanthin             | 59.54 ± 54.91     |
| Lycopene                    | 218.86 ± 176.80   |
| α-carotene                  | 15.19 ± 14.92     |
| β-carotene                  | 80.46 ± 82.13     |
| Total carotenoids           | 935.02 ± 474.95   |

Association between carotenoids and both peripheral and central [NAD(H)]

A significant positive association was found between lycopene and both plasma ($P < 0.01$, $r = 0.50$, $n = 38$) and CSF ($P < 0.01$, $r = 0.50$, $n = 37$) [NAD(H)] (Figure 5). These relationships remained even after controlling for age and gender ($P < 0.001$, $R^2 = 0.31$; $P < 0.001$, $R^2 = 0.21$ respectively). A 1% increase in lycopene was associated, on average, with a 0.20% increase in plasma [NAD(H)]. Likewise a tenfold increase in lycopene was associated with a 48.4 μg/mL increase in CSF [NAD(H)].

After controlling for age and gender a positive association between total carotenoids and plasma NAD(H) levels was also observed ($P = 0.03$, $R^2 = 0.12$, $n = 37$) (Figure 5C). A 1% increase in total carotenoids was associated, on average, with a 0.21% increase in plasma [NAD(H)]. Plasma total carotenoids were positively associated with CSF [NAD(H)] ($P = 0.05$, $r = 0.33$, $n = 37$), however this did not remain statistically significant after controlling for age and gender. No associations were found between plasma [NAD(H)], CSF [NAD(H)] and any other individual carotenoid.

### Discussion

Neuroinflammation and oxidative stress are established pathological features of most neurodegenerative disorders. While the consumption of foods rich in carotenoids, known to possess antioxidant and inflammatory modulating properties, has been linked to a reduced risk of cognitive decline...
[40], surprisingly there is limited research on the effect of carotenoids on neuroinflammation and oxidative stress. To our knowledge this is the first study to investigate the association between peripheral carotenoid concentrations and CNS markers of oxidative stress and inflammation in humans without CNS pathology.

As expected, high plasma lycopene and total carotenoid concentrations were associated with reduced plasma IL-6 levels. This is consistent with epidemiologic studies reporting carotenoid concentrations to be inversely associated with peripheral markers of inflammation [52]. While further research into the mechanism of carotenoid mediated inflammation is required, it has been demonstrated that a variety of carotenoids, including lycopene and lutein inhibit cytokine production via suppressing ROS stimulated NF-κB activation [53-56].

While major contributors to plasma TAC are uric acid and albumin [57], the positive correlation observed between plasma TAC and both α-carotene and β-carotene indicate that these carotenoids contribute to peripheral antioxidant defences. However, their capacity to mitigate against both lipid and DNA damage in vivo is questionable as no inverse associations were observed between carotenes and either plasma F2-isoprostane or 8-OHdG respectively. Previous evidence for an association between the carotenes and markers of lipid and DNA oxidative damage is mixed, with some studies showing a significant protective effect and others finding no significant association [58-61]. For example van den Berg and colleagues reported that while a three-week plant-based diet increased serum levels of carotenoids, including α-carotene and β-carotene, and increased TAC, consistent with results from this study, no effects were observed on any plasma marker of oxidative damage to lipids, proteins and DNA [61].

A number of carotenoids, including β-cryptoxanthin, lycopene and β-carotene, are thought to cross the blood brain barrier and modulate inflammation [62,37]. In this

![Figure 2](http://www.jneuroinflammation.com/content/11/1/117)
study a novel inverse association between β-cryptoxanthin and CSF IL-6 was observed. Similarly an increase in total carotenoids was also associated with reduced CSF IL-6 levels. This is consistent with in vitro work by others showing that β-cryptoxanthin significantly attenuates both the release and transcription of various cytokines [63,64]. Astaxanthin, another member of the carotenoid xanthophyll family, has also been shown to decrease IL-6 mRNA in activated microglia [65].

In contrast to the inverse associations observed between carotenoids and IL-6, an increase in plasma α-carotene was associated with a statistically significant increase in CSF TNF-α. A positive, though not statistically significant trend was also observed between β-carotene and CSF TNF-α. While evidence of the moderating effect of carotenoids on inflammation is growing, consistent with results from this study, a small number of in vitro and ex vivo studies have reported that β-carotene can increase the secretion of TNF-α from monocytes and macrophages [66,67]. Although no known studies have investigated the potential for α-carotene to likewise promote TNF-α secretion, the structural similarity between both carotene types suggest this possibility and is consistent with the data presented in this manuscript, though further research is required to verify this observation.

TNF-α is a multifunctional, pleiotropic cytokine initially identified as a potent regulator of cellular activity during an immune response. Although traditionally considered toxic and known to initiate neuronal apoptosis when elevated [13] in healthy brain tissue under non-inflammatory conditions, physiological TNF-α levels below approximately 20 (pg/mL) appear to have positive neuromodulatory activity [17,68-72]; being involved in synaptic scaling, cell signalling and a number of behavioural and autonomic processes [17-21]. Under certain circumstances TNF-α has also displayed neuroprotective properties such as preventing Aβ toxicity [15]. While the role of TNF-α in normal brain function is yet to be fully elucidated, considered together, these studies indicate that physiological levels of TNF-α, as observed in this study (2.69 pg/mL ± 0.68 SD) may play a role in maintaining neural homeostasis. Therefore, our finding of a positive association between the carotenoids and TNF-α levels (within the lower physiological range) likely do not reflect increased inflammation, but rather promotion of the healthy neuromodulatory function of TNF-α.

There is a growing interest in understanding the role and mechanism of the carotenoids as inhibitors of oxidative stress. Indeed evidence suggests that the ability of

Figure 3 Positive association between cerebrospinal fluid (CSF) TNF-α and plasma α-carotene. A significant positive association exists between plasma α-carotene and CSF TNF-α ($P = 0.02$, $R^2 = 0.10$, $n = 36$). Comparisons were made using multiple linear regression controlling for age and gender.

Figure 4 Positive association between plasma total antioxidant capacity (TAC) and (A) plasma α-carotene (B) plasma β-carotene. (A) A significant positive association exists between plasma α-carotene and plasma TAC ($P = 0.01$, $R^2 = 0.14$, $n = 33$). Comparisons were made using multiple linear regression controlling for age and gender. (B) A significant positive association exists between plasma β-carotene and plasma TAC ($P < 0.001$, $R^2 = 0.32$, $n = 33$). Comparisons were made using multiple linear regression controlling for age and gender.

Figure 5 Positive association between cerebrospinal fluid (CSF) TNF-α and plasma β-carotene. A significant positive association exists between plasma β-carotene and CSF TNF-α ($P = 0.02$, $R^2 = 0.10$, $n = 36$). Comparisons were made using multiple linear regression controlling for age and gender.
carotenoids to combat oxidative stress does not solely rely on their capacity to quench free radicals. Recently lycopene, a potent singlet oxygen ($1^O_2$) quencher [73], has been reported to restore PARP activity after deltamethrin-induced testicular injury in rats [74]. Further Apo-10' lycopenoic acid, a lycopene metabolite, has been shown in murine models to increase sirtuin 1 (SIRT1) mRNA and protein levels [75]. Importantly, both PARP and SIRT1 use NAD$^+$ as the primary substrate for their activities. We report for the first time a significant positive association between lycopene and both plasma and CSF NAD(H) levels, which remained even after controlling for age and gender. While further investigation is required, we postulate that by quenching ROS, lycopene reduces DNA damage, preventing PARP over-activation, and hence preservation of central NAD$^+$ stores.

NAD$^+$ is a ubiquitous molecule that is necessary for a number of vital cellular processes. In addition to its role in classical energy production and many cellular reactions as a redox couple, NAD$^+$ also serves, as previously mentioned, as a substrate for the sirtuin and PARP family of enzymes and the immune linked NAD$^+$ glycohydrolases (CD38) [76-78]. As a group, these NAD$^+$ dependent enzymes help modulate circadian rhythms, insulin secretion, genomic stability and cell longevity [79-83]. As NAD(H) levels impact at least PARP and SIRT1 activity, our observation that lycopene correlates with increased NAD(H) availability within the brain suggests that consumption of this carotenoid may improve cell metabolic and genomic stability, decreasing an individual’s susceptibility to neurodegenerative disease. This is of potential significant relevance in light of observations by others that higher levels of NAD+ correlate with reduced synaptic loss and increased neuronal viability [84,85], and the need to find effective strategies to maintain cell function in the aging brain.

While the observations reported in this study are statistically valid, it is recognised that these associations have been obtained from a modest number of matched whole blood and CSF samples, potentially limiting sensitivity. As a result, some relationships may have been obscured; for example, although no statistically significant association between

---

**Figure 5** Association between carotenoids and increased levels of peripheral and central (NAD(H)). (A) A significant positive association exists between lycopene and plasma [NAD(H)] ($P < 0.001$, $R^2 = 0.31$, $n = 38$). Comparisons were made using multiple linear regression controlling for age and gender. (B) A significant positive association exists between lycopene and CSF [NAD(H)] ($P < 0.001$, $R^2 = 0.21$, $n = 37$). Comparisons were made using multiple linear regression controlling for age and gender. (C) A significant positive association exists between total carotenoids and plasma [NAD(H)] ($P = 0.03$, $R^2 = 0.12$, $n = 37$). Comparisons were made using multiple linear regression controlling for age and gender.
carotenoids and specific biomarkers of lipid and DNA damage was found, a number of expected inverse trends were observed that may have reached statistical significance if sample numbers were increased. In addition, some observed associations did not remain significant after controlling for age and gender (for example, between CSF IL-6 and serum total carotenoids) which may yet prove significant in a larger cohort study. In the case of age, this may also reflect the relative inability of carotenoids to exert enough anti-inflammatory effect on their own to combat the known age associated acceleration in inflammation and oxidative stress [47,86]. Nevertheless, the reported associations in this study are generally consistent with the limited number of previously published observations and represent the first data linking carotenoid levels with changes in [NAD(H)] and inflammatory/oxidative stress markers in the healthy CNS.

Conclusion
An extensive body of evidence now indicates that oxidative stress and inflammation play a central role in the development of neurodegenerative disorders. While the consumption of foods rich in carotenoids have been linked to a reduced risk of this type of neuropathology, limited research is available detailing their association with inflammation and oxidative stress levels within the human CNS. This study provides evidence for the first time that plasma carotenoids may modulate CSF levels of inflammatory cytokines in healthy humans and reports a link between increased plasma carotenoid concentrations and reduced oxidative activity. We also provide novel evidence that lycopene may influence levels of the essential pyridine nucleotide NAD(H) in both the plasma and the CSF. This data therefore suggests that higher carotenoid intake may assist in the maintenance of brain health, however further research (both cross-sectional and longitudinal) is required to confirm this proposition.

Abbreviations
- 8-OHdG: 8-hydroxy-2′-deoxyguanosine
- Aβ: beta amyloid
- AD: Alzheimer’s disease
- ATP: adenosine triphosphate
- CSF: cerebrospinal fluid
- ELISA: Enzyme-Linked Immunosorbent Assay
- GC-MS: gas chromatography-mass spectrometry
- HPLC: high performance liquid chromatography
- IL-6: interleukin-6
- IL-1β: interleukin-1 beta
- IL-1 RA: interleukin-1 receptor antagonist
- NAD+: total nicotinamide adenine dinucleotide
- NADH: nicotinamide adenine dinucleotide
- PARP: poly(ADP-ribose) polymerase-1
- RNS: reactive nitrogen species
- ROS: reactive oxygen species
- SIRT1: sirtuin 1
- TAC: total antioxidant capacity
- TNF-α: tumor necrosis factor alpha

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
JG participated in the design and coordination of the study, acquisition and analysis of samples, analysis and interpretation of data and drafted the manuscript. MG conducted the carotenoid analysis and revised the manuscript. TAM carried out the F2-isoprostane analysis and revised the manuscript. AB was involved in the analysis and interpretation of data and manuscript revision. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by a grant to R Grant and J Guest from the BUPA Health Foundation. We would like to thank the anaesthesiists of Sydney Adventist Hospital who kindly assisted in the collection of all samples.

Author details
1 Australasian Research Institute, Sydney Adventist Hospital, Sydney, NSW, Australia.
2 Department of Medical Sciences, Faculty of Medicine, University of New South Wales, Wallace Wurth Building, office #203, Sydney, NSW 2052, Australia.
3 Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
4 School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia.
5 School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Perth, WA, Australia.
6 Faculty of Science, Macquarie University, Sydney, NSW, Australia.

Received: 18 December 2013 Accepted: 27 May 2014

Published: 1 July 2014

References
1. Glass CK, Saiko K, Winner B, Marchetto MC, Gage FH: Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918–934.
2. Lin MT, Beal MF: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:797–799.
3. Taskin BI, Mellon SH, Dhabhar FS, Epel ES, Puttermann E, Su Y, Burke HM, Reus R, Rosser R, Hamilton SP, Nelson JC, Wolkowitz OM: Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun 2013, 31:143–152.
4. Ilyasova D, Ivanova A, Morrow JD, Cesari M, Pahor M: Correlation between two markers of inflammation, serum C-reactive protein and interleukin 6, and indices of oxidative stress in patients with high risk of cardiovascular disease. Biomarkers 2008, 13:41–51.
5. Fumey SJ, Kronenberg D, Simmons A, Güntert A, Dobson RJ, Protsi P: Combinatorial markers of mild cognitive impairment conversion to Alzheimer’s disease - cytokines and MRI measures together predict disease progression. J Alzheimers Dis 2011, 26(Suppl 3):395–405.
6. Collins LM, Toulouse A, Connor TJ, Nolan YM: Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 2012, 62:2154–2168.
7. Evans MC, Couch Y, Sibson N, Turner MR: Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2013, 53:3–41.
8. Suddath TL, Schmitt FA, Nelson PT, Witcock DM: Neuroinflammatory phenotype in early Alzheimer’s disease. Neurobiol Aging 2013, 34:1051–1069.
9. Boissonneault V, Filali M, Lessard M, Marlon R, Wolkowitz OM: Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 2012, 62:2154–2168.
10. Evans MC, Couch Y, Sibson N, Turner MR: Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2013, 53:3–41.
11. Suddath TL, Schmitt FA, Nelson PT, Witcock DM: Neuroinflammatory phenotype in early Alzheimer’s disease. Neurobiol Aging 2013, 34:1051–1069.
12. Boissonneault V, Filali M, Lessard M, Marlon R, Wolkowitz OM: Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 2012, 62:2154–2168.
13. Evans MC, Couch Y, Sibson N, Turner MR: Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2013, 53:3–41.
14. Suddath TL, Schmitt FA, Nelson PT, Witcock DM: Neuroinflammatory phenotype in early Alzheimer’s disease. Neurobiol Aging 2013, 34:1051–1069.
15. Boissonneault V, Filali M, Lessard M, Marlon R, Wolkowitz OM: Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacology 2012, 62:2154–2168.
16. Evans MC, Couch Y, Sibson N, Turner MR: Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol Cell Neurosci 2013, 53:3–41.
17. Suddath TL, Schmitt FA, Nelson PT, Witcock DM: Neuroinflammatory phenotype in early Alzheimer’s disease. Neurobiol Aging 2013, 34:1051–1069.
15. Barger S, Horster D, Furukawa K, Goodman Y, Kriegstein J, Mattson M: Tumor necrosis factors alpha and beta protect against APP toxicity: evidence for involvement of a kβ-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci U S A 1995, 92:9328–9332.

16. Liu Z, Qiu YH, Li B, Ma SH, Peng YP: Neuroprotection of interleukin-6 against NMDA-induced apoptosis and its signal-transduction mechanisms. Neuroreport 2011, 22:1590–1594.

17. Vidkovic L, Bockaert J, Jacque C: ‘Inflammatory’ cytokines: neumodulators in normal brain? J Neurochem 2000, 74:457–471.

18. Raion CL, Borsov AS, Woolwine BJ, Massung B, Vogt G, Miller AH: Interferon-α effects on duusal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behaviour. Mol Psychiatry 2010, 15:535–547.

19. Shoham S, Davienne D, Cady AB, Dinarello CA, Krueger JM: Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. Am J Physiol 1987, 253:R142–R149.

20. Stallwagen D, Malenka RC: Supracortical scaling mediated by glial TNF-α[alpha]. Nature 2005, 440:1054–1059.

21. Eder J: Tumour necrosis factor alpha and interleukin 1 signalling: do MAPKK kinases connect it all? Biochim Biophys Acta Sci 1997, 1351:352–405.

22. McCoy M, Tansey MG: TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5:45.

23. Satoh T, Nakamura S, Taga T, Matsuda T, Hirano T, Kishimoto T, Kazuo Y: Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol 1998, 8:3546–3549.

24. Biber K, Pinto-Duarte A, Wittendorp MC, Dolga AM, Fernandes CC, Von Frijtag Drabble Kurzel J, Keijer JN, de Vries R, Ijmnam AP, Ribeiro JA, Isel U, Sebastiao AM, Bodecke HGWK: Interleukin-6 upregulates neuronal adenosine a1 receptors: implications for neumodulation and neuroprotection. Neuropsychopharmacol 2008, 33:2273–2250.

25. Wassmann S, Stumpf M, Strehlow K, Schieffer B, Böhm M, Nickenig G: Dioleoylphosphatidylserine promotes neuritic extension and neurite outgrowth in embryonic-derived neurons, hippocampal neurons and cultured neurons. J Neurosci Res 2004, 74:534–541.

26. Petit-Frère C, Clingen PH, Grewe M, Krutzmann J, Roza L, Arlett CF, Green MHL: Induction of interleukin-6 production by ultraviolet radiation in normal human epidermal keratinocytes and in a human keratinocyte cell line is mediated by DNA damage. J Invest Dermatol 1998, 111:354–359.

27. Suematsu N, Tsutsui H, Wen J, Kang D, Irieuchi M, Ide T, Hayashida S, Shiomi T, Kubota T, Hamasaki N, Takehashi A: Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2003, 107:1418–1423.

28. Hallwell B: Oxidative stress and neurodegeneration: where are we now? J Neurochem 2006, 97:1634–1658.

29. Sies H: Introductory remarks. J Neurochem 2008, 104:S1.

30. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari 2006, J Neurochem 52:1658.

31. Nakagawa K, Tsuduki T, Suzuki T, Arai H, Miyazawa T: Significance of lutein in red blood cells of Alzheimer’s disease patients. J Alzheimers Dis 2012, 28:593–600.

32. Nakagawa K, Araki H, Tadate K, Sookwong P, Arai H, Miyazawa T: Antioxidant effect of lutein towards phospholipid hydroperoxidation in human erythrocytes. British J Nutr 2006, 95:1707–1720.

33. Guest J, Garg M, Bilgin A, Grant R: Relationship between central and peripheral fatty acids in humans. Lipids Health Dis 2013, 12:79–87.

34. Bremforsy C, Swan M: An improved cycling assay for nicotinamide adenine dinucleotide. Anal Biochem 1973, 53:452–458.

35. Grant RS, Kapoor V: Murine glial cells regenerate NAD+, after peroxide induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem 1998, 70:1759–1763.

36. Masuodi H, Grant R, Braidy N, Guest J, Fansworth B, Grant R: Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One 2012, 7:e2357.

37. Mori TA, Croft KD, Puddieb J, Bellin L: An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. Anal Biochem 1999, 286:117–125.

38. Banks AE, Corcoran TB, Mas E, Durand T, Galano J-M, Roberts LJT, Pache M, Muchatuta NA, Phillips M, Mori TA: Is there a role for isofurans and neuroprostanes in pre-eclampsia and normal pregnancy? Antioxid Redox Signal 2012, 16:165–169.

39. Bara BA, Kostic D, Olsen J: New simplified procedures for the extraction and simultaneous high performance liquid chromatographic analysis of retinol, tocopherols and carotenoids in human serum. J Chrom 1993, 617:257–264.

40. Burrows TL, Warren JM, Coiyas K, Garg ML, Collins CE: Validation of overweight children's fruit and vegetable intake using plasma carotenoids. Obesity 2009, 17:162–168.

41. Barchet W, Corcoran TB, Mas E, Durand T, Galano J-M, Roberts LJT, Pache M, Muchatuta NA, Phillips M, Mori TA: Is there a role for isofurans and neuroprostanes in pre-eclampsia and normal pregnancy? Antioxid Redox Signal 2012, 16:165–169.

42. Armoza A, Haim Y, Basri A, Wolk T, Parin E: Tomato extract and the carotenoids lycopene and lutein improve endothelial function and attenuate inflammatory NF-κB signaling in endothelial cells. J Hypertens 2012, 31:549–529.

43. Bai SK, Lee SJ, Na HJ, Ka HS, Han JA, Lee H, Kwon YG, Chong CK, Kim YM: β-carotene inhibits inflammatory gene expression in lipopolysaccharide-stimulated macrophages by suppressing redox-based NF-κB activation. Exp Mol Med 2005, 37:323–334.

44. Kim GY, Kim JH, Ahn SC, Lee HJ, Moon DG, Lee CM, Park YM: Lycopene suppresses the lipopolysaccharide-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and nuclear factor-kappaB/FOXOs. Immunology 2004, 113:263–271.

45. Rothstein JD: Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol 2009, 65(suppl 1):103–110.

46. Sun F, Gobbel G, Li WJ, Chen J: Molecular mechanisms of DNA damage and repair in ischemic neuronal injury. Mech Ageing Dev 2012, 133:186–194.

47. Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, Swanson RA: NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neuro 2010, 30:2967–2978.

48. Evans DA, Funkenstein HH, Albert MS, Schein PA, Cook NR, Chown MJ, Hebert LEH, Hennekens CH, Taylor JO: Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA 1989, 262:2551–2556.

49. Moghal S, Rajput AH, D’Carrick J, Rajput R: Prevalence of movement disorders in elderly community residents. Neuropsychobiology 1994, 31:75–178.

50. Johnson RJ, Stewart RJ, Schallch W, Wittwer J, Hausman DB, Davisy A, Johnson MA, Green RC, Gearing M, Pooh LW: Serum carotenoids as a biomarker for carotenoid concentrations in the brain. FASEB 2011, 25:s3442.

51. Qu M, Chen C, Li M, Peo L, Chu F, Yang J, Yu Z, Wang D, Zou Z: Protective effects of lycopene against amyloid β-induced neurotoxicity in cultured rat cortical neurons. Neurosci Lett 2011, 503:286–290.
60. Hininger IA, Meyer-Wenger A, Moser U, Wright A, Southon S, Thornham D, Chopra M, Van Den Berg H, Olmedilla F, Favier AE, Roussel AM. No significant effects of lutein, lycopene or ß-carotene supplementation on biological markers of oxidative stress and LDL oxidizability in healthy adult subjects. J Am Coll Nutr 2001, 20:232–238.

61. van den Berg R, Van Vliet T, Braamsmans WNR, Grubben NH, Vees WH, Roza L, Haenen GRF, Bart A, van den Berg H: A vegetable/fruit concentrate with high antioxidant capacity has no effect on biomarkers of antioxidant status in male smokers. J Nutr 2001, 131:1722–1747.

62. Unno K, Sugiuira M, Ogawa K, Takabayashi F, Toda M, Sakamura M: ß-Cryptoxanthin, plentiful in Japanese mandarin orange, prevents age-related cognitive dysfunction and oxidative damage in senescence-accelerated mouse brain. Biol Pharm Bull 2011, 34:311–317.

63. Nishigaki M, Yamamoto T, Ichikawa H, Honjo KI, Yamamoto K, Oseko F, Kita M, Oda Y, Kanamura N: ß-cryptoxanthin regulates bone resorption related cytokine production in human periodontal ligament cells. Arch Oral Biol 2013, 58:880–886.

64. Katsuura S, Imamura T, Bando N, Yamanishi R: ß-Carotene and ß-cryptoxanthin but not lutein evoke roxob and immune changes in RAW264 murine macrophages. Mol Nutr Food Res 2009, 53:1396–1405.

65. Kim YH, Koh HK, Kim DS: Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-κB-mediated signals in activated microglia. Int Immunopharmacol 2010, 10:1560–1572.

66. Hughes DA, Wright AJA, Finglas PM, Peerless ACJ, Bailey AL, Astley SB, Pinder AC, Southon S. The effect of ß-carotene supplementation on the immune function of blood monocytes from healthy male nonsmokers. J Lab Clin Med 1997, 129:309–317.

67. Yeh S-L, Wang H-M, Chen P-Y, Wu T-Z: Interactions of ß-carotene and flavonoids on the secretion of pro-inflammatory mediators in an in vitro system. Chem-Biol Interact 2009, 179:386–393.

68. Tarkowski E, Blennow K, Wallin A, Tarkowski A: Intracerebral production of tumor necrosis factor-α local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999, 19:223–230.

69. Tarkowski E, Tullberg M, Fredman P, Wikkelso C: In the regulation of nuclear functions. J Nutr 2013, 143:2001–2009.

70. Tang R-B, Lee B-H, Chung R-L, Chen S-J, Wong T-T: Interleukin-1ß and tumor necrosis factor-α in cerebrospinal fluid of children with bacterial meningitis. Child Nerv Syst 2001, 17:453–456.

71. Kwon KY, Jeon B-C: Cytokine levels in cerebrospinal fluid and delayed ischemic deficits in patients with aneurysmal subarachnoid haemorrhage. J Korean Med Sci 2011, 26:774–780.

72. Perry SW, Dewhurst S, Bellizzi MJ, Geldard HA: Tumor necrosis factor-alpha in normal and diseased brain: conflicting effects via intraneuronal receptor crosstalk? J Neurosci 2002, 22:611–624.

73. Di Mascio P, Kaiser S, Sies H: Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 1989, 274:532–538.

74. Ismail MF, Mohamed HM: Modulatory effect of lycopene on deltaminethrin-induced testicular injury in rats. Cell Biochem Biophys 2013, 65:425–432.

75. Chung J, Koo K, Lian F, Hu KQ, Ernst H, Wang XD: Apo-10-lycopenic acid, a lycopene metabolite, increases sirtuin 1 mRNA and protein levels and decreases hepatic fat accumulation in ddY mice. J Nutr 2012, 142:405–410.

76. D’Amours D, Desnoyers S, D’Souza I, Poirier GG: Poly(ADP-ribose)ylation reactions in the regulation of nuclear functions. Biochem J 1999, 342:249–268.

77. Zhao X, Allison D, Condron B, Zhang F, Gheyi T, Zhang A, Ashok S, Russell M, MacEwan I, Qian Y, Jamison JA, Luz JG: The 2.5 Å crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD⁺) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition. J Med Chem 2013, 56:963–969.

78. Szarkowska L, Ereinska M: Energy-linked reduction of the mitochondrial nicotinamide-adenine. Acta Biochim Pol 1965, 2:179–186.

79. Finkel T, Deng CX, Mostoslavsky R: Recent progress in the biology and physiology of sirtuins. Nature 2009, 460:587–591.

80. Liang F, Kume S, Koya D: SIRT1 and insulin resistance. Nat Rev Endocrinol 2009, 5:367–373.

81. Nakahata Y, Sahar S, Astaiva G, Kaliouva M, Sassone-Corsi P: Circadian control of the NAD⁺ salvage pathway by CLOCK-SIRT1. Science 2009, 324:654–657.

82. Ramsey KM, Yoshino J, Brace CS, Abramart D, Kobayashi Y, Marcheva B, Horig K, Chong J, Buh E, Lee C, Takahashi JS, Imai S, Bass J: Circadian clock feedback cycle through NAMPT mediated NAD⁺ biosynthesis. Science 2009, 324:651–654.

83. Schreiber V, Dantzer F, Ame JC, de Murcia G: Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006, 7:517–528.

84. Deleglise B, Lassus B, Soucyve Y, Alleaune-Butaux A, Hjorth JJ, Vignes M, Schneider B, Brugger B, Vlosy J-L, Peyrin J-M: Synapto-protective drugs evaluation in reconstructed neuronal network. PLoS One 2013, 8:e71103.

85. Won SJ, Choi BY, Yoo BH, Sohn M, Ying W, Swanson RA: Suh SW: Prevention of traumatic brain injury-induced neuron death by intranasal delivery of nicotinamide adenine dinucleotide. J Neurotrauma 2012, 29:1401–1409.

86. Guest J, Grant R, Mori TA, Croft KD: Changes in oxidative damage, inflammation and [NAD(H)] with age in cerebrospinal fluid. PLoS One 2014, 9:e85335.

Cite this article as: Guest et al.: Cerebrospinal fluid levels of inflammation, oxidative stress and NAD⁺ are linked to differences in plasma carotenoid concentrations. Journal of Neuroinflammation 2014 11:17.